Holen Sie sich die Stockscreener-App
4.50
7.02%
-0.34
Schlusskurs vom Vortag:
$4.84
Offen:
$4.83
24-Stunden-Volumen:
103.64K
Relative Volume:
0.57
Marktkapitalisierung:
$93.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.17M
KGV:
-0.3879
EPS:
-11.6
Netto-Cashflow:
$-91.71M
1W Leistung:
-2.60%
1M Leistung:
+4.90%
6M Leistung:
-37.76%
1J Leistung:
-75.00%
1-Tages-Spanne:
$4.46
$4.85
1-Wochen-Bereich:
$4.20
$4.905
52-Wochen-Spanne:
$3.52
$18.50
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Firmenname
Adverum Biotechnologies Inc
Sektor
Branche
Telefon
(650) 649-1004
Adresse
100 CARDINAL WAY, REDWOOD CITY, CA
Vergleichen Sie ADVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.50 | 93.61M | 0 | -117.17M | -91.71M | -11.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Hochstufung | Truist | Hold → Buy |
| 2021-07-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Herabstufung | Truist | Buy → Hold |
| 2020-12-16 | Eingeleitet | UBS | Neutral |
| 2020-11-12 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-05 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-09-13 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-06-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2018-11-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Herabstufung | SunTrust | Buy → Hold |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Eingeleitet | SunTrust | Buy |
| 2018-02-15 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Adverum Biotechnologies Inc Aktie (ADVM) Neueste Nachrichten
Adverum Biotechnologies Inc expected to post a loss of $1.36 a shareEarnings Preview - TradingView
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - Marketscreener.com
Adverum launches phase 3 trial for wet AMD gene therapy By Investing.com - Investing.com UK
Can This One-Time Gene Therapy Revolutionize Wet AMD Treatment? Adverum's Phase 3 Trial Begins - StockTitan
Adverum Biotechnologies initiates ARTEMIS study - TipRanks
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum biotechnologies sees $1.44 million stock purchase by major shareholder - Investing.com
How Adverum is Attracting Talent: New Employees Receive $186,000 in Equity Grants - StockTitan
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Target Price at $27.83 - MarketBeat
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference - The Manila Times
Gene Therapy Developer Adverum to Showcase Ocular Disease Pipeline at Major Healthcare Conference - StockTitan
Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
3 US Penny Stocks With Market Caps Below $400M - Yahoo Finance
The Sonic Fund Solicits Proxies from Shareholders of Adverum Biotechnologies -April 13, 2021 at 04:16 pm EDT - Marketscreener.com
Adverum Biotechnologies (NASDAQ:ADVM) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
4D’s new data in wet AMD bolster its phase III study vision - BioWorld Online
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Gene Therapy Pioneer Adverum Takes Center Stage at Major Healthcare Conference - StockTitan
ADVM stock touches 52-week low at $4.01 amid market challenges - MSN
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $27.83 - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $27.83 Average PT from Analysts - Defense World
Barclays PLC Buys 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Comparing Adverum Biotechnologies (NASDAQ:ADVM) & Pluri (NASDAQ:PLUR) - Defense World
Adverum Biotechnologies stock hits 52-week low at $4.4 - Investing.com
Adverum Biotechnologies stock hits 52-week low at $4.4 By Investing.com - Investing.com South Africa
Geode Capital Management LLC Sells 16,731 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Barclays PLC Purchases 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
State Street Corp Boosts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short Interest - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Large Increase in Short Interest - MarketBeat
Adverum Biotechnologies stock hits 52-week low at $4.61 - Investing.com
Adverum Biotechnologies (NASDAQ:ADVM) Cut to Sell at StockNews.com - Defense World
StockNews.com Downgrades Adverum Biotechnologies (NASDAQ:ADVM) to Sell - MarketBeat
Where are the Opportunities in (ADVM) - Stock Traders Daily
Fmr LLC Lowers Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Sold by Fmr LLC - MarketBeat
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 11.1% in November - MarketBeat
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 11.1% - Defense World
ADVM stock touches 52-week low at $5.61 amid market challenges - Investing.com
StockNews.com Upgrades Adverum Biotechnologies (NASDAQ:ADVM) to Hold - Defense World
Finanzdaten der Adverum Biotechnologies Inc-Aktie (ADVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adverum Biotechnologies Inc-Aktie (ADVM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Feb 28 '25 |
Buy |
4.60 |
85,068 |
391,015 |
2,604,820 |
| Leonard Braden Michael | 10% Owner |
Feb 27 '25 |
Buy |
4.46 |
86,802 |
387,094 |
2,519,752 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
7.15 |
85,800 |
613,470 |
2,268,064 |
| Leonard Braden Michael | 10% Owner |
Jul 17 '24 |
Buy |
7.75 |
135,546 |
1,049,926 |
2,101,546 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
9.11 |
80,718 |
735,736 |
2,182,264 |
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):